Anti-lipolysis-stimulated lipoprotein receptor monoclonal antibody as a novel therapeutic agent for endometrial cancer.

Yoshikazu NagaseKosuke HiramatsuMasashi FunauchiMayu ShiomiTatsuo MasudaMamoru KakudaSatoshi NakagawaAi MiyoshiShinya MatsuzakiEiji KobayashiToshihiro KimuraSatoshi SeradaYutaka UedaTetsuji NakaTadashi Kimura

Published in: BMC cancer (2022)

Our results suggest that LSR contributes to tumor growth, invasion, metastasis, and poor prognosis of EC through MAPK signaling. Anti-LSR mAb is a potential therapeutic agent for EC.

Keyphrases

monoclonal antibody
poor prognosis
endometrial cancer
long non coding rna
adipose tissue
signaling pathway
oxidative stress
cell migration
pi k akt
cell proliferation
low density lipoprotein